Chronix news

New study shows blood test detected cancer metastasis

Chronix Biomedical

RESEARCH BY CHRONIX BIOMEDICAL AND INSTITUTE OF VETERINARY MEDICINE GÖTTINGEN HIGHLIGHTS CELL-FREE DNA ANALYSIS FOR CANCER MINIMAL RESIDUAL DISEASE San Jose, CA and Göttingen, Germany—September 30, 2013—Researchers from the University Göttingen Institute of Veterinary Medicine...

New test increases sensitivity of HPV detection in cancer

Newswise

Newswise — CHICAGO (May 30, 2014) – Researchers from Sanford Health and Chronix Biomedical today announced that results from a pilot study demonstrating the utility of a new cancer panel to detect previously undetected viral...

Changes in tumor cell-free DNA copy number instability (CNI) predict therapeutic response to immunotherapy

Chronix Biomedical

San Jose, CA, USA and Göttingen, Germany (19 May, 2016) – Chronix Biomedical, Inc., a developer of blood-based molecular diagnostics, today announces positive data from a blinded proof of concept clinical study, assessing the utility...

Chronix Biomedical to present clinical data on its cell-free DNA approach as an early predictor of response to immunotherapy at the ASCO Annual Meeting

Chronix Biomedical

San Jose, CA, USA and Göttingen, Germany (3 May, 2016) – Chronix Biomedical, Inc., a developer of blood-based molecular diagnostics, today announces that it will present clinical data relating to its cell-free DNA copy number...

Changes in tumor cell-free DNA copy number instability (CNI) predict therapeutic response in metastatic cancers

Chronix Biomedical

San Jose, CA, USA and Göttingen, Germany (April 18, 2016) – Chronix Biomedical, Inc., a developer of blood-based molecular diagnostics, today presents positive data from a blinded proof of concept clinical study, assessing the utility...